Background. Healthcare-associated infections due to multiply-resistant organisms cause significant morbidity and mortality in acute care settings. Antimicrobial stewardship programs (ASP) are one practice used to limit resistance and are especially crucial given the lack of new antimicrobials in development. The aim of this study was to describe the presence of ASP in a national sample of acute care hospitals and examine the engagement of Infection Preventionists (IPs) in antimicrobial stewardship activities.
Background. In July 2016, the FDA updated its boxed warning for fluoroquinolones (FQ) in light of ongoing safety concerns. Our objective was to examine trends in FQ and other antibiotic prescribing before and after the warning.
Methods. We analyzed electronic health records for inpatient, outpatient, and emergency department encounters during April 2014-August 2017 in the University of North Carolina Health Care System (N = 14,524,758 encounters). Patients under age 2 years were excluded. We estimated FQ prescribing rates per 1,000 encounters (henceforth, "/1,000"). Using an interrupted time series approach, we fit segmented linear regression models to assess trends before and after the FDA warning, accounting for seasonality and autocorrelated errors. We evaluated trends by gender, age, and point of care, and explored potential replacement of FQs by other antibiotics after the warning.
Results. The average FQ prescribing rate was 9.2/1,000 (95% CI 3.8, 14.7). Before the warning (April 2014-July 2016), the FQ prescribing rate decreased by 0.6/1,000/year (95% CI 0.3, 0.9) (figure). At the time of the warning, the slope for the FQ prescribing rate steepened by 0.8/1,000/year (95% CI −0.1, 1.7); as a result, after the warning (July 2016-August 2017), the rate decreased by 1.4/1,000/year (95% CI 0.7, 2.1). FQ prescribing was most common among adults age ≥65 (mean rate 12.2/1,000), but relative trends were similar across age and gender. Average FQ prescribing rates were highest in the inpatient setting (40.5/1,000) compared with emergency (18.3/1,000) and outpatient (6.2/1,000) encounters; relative trends were similar across settings. Rates for other common antibiotics did not increase after the warning, either overall (figure) or in any subgroup. Results were robust to sensitivity analysis for lagged effects. Additionally, the interpretation of results is anchored by trends for inhaled corticosteroids, which we analyzed as a negative control (figure).
Conclusion. The July 2016 FDA warning on FQs was associated with a small deceleration in FQ prescribing. There was no evidence of replacement by antibiotics with similar indications. We observed no evidence of heterogeneity across subgroups defined by gender, age, and point of care. Future research should assess the potential impact of the warning in clinically defined subgroups in various settings.
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No reported disclosures. Methods. With support from VA Antimicrobial Stewardship Task Force and NHSN, we deployed one team to focus on implementation and another on technical aspects. We used an iterative recruitment approach with four cohorts to date (Tiers), starting with highly engaged facilities with strong stewardship infrastructure. Our implementation approach (Figure 1 ) was based on the Promoting Action on Research Implementation (PARiHS) framework for successful implementation of evidence into clinical practice. We evaluated our implementation with focus groups conducted using Skype chat to collect feedback from participants about the implementation process. Group 1 contained six participants from Tiers 1 and 2. Group 2 had three participants from Tiers 3 and 4. Questions were constructed using the PARiHS framework (Table 1 ). An implementation team member conducted interviews, monitored the discussion, then coded major themes of responses.
Implementation of the National
Results. To date, there are over 90 facilities reporting AU to NHSN. Major themes to responses are summarized in Table 1 . Overall, focus group participants were supportive of the program, but there were differences between early and later adopters.
Conclusion. A coordinated, centralized approach to facilitating implementation of NHSN AU reporting has been successful so far. Major themes from focus group responses did differ in some categories depending on tier in a way that appears concordant with the theory diffusion of innovation, e.g., early tiers were enthusiastic despite a lack of institutional support while later tiers reported being motivated by regulatory requirements and had solid institutional support. More research would further inform how to efficiently implement complex programs in large systems.
